Key result
Epigenetic modifications, including non-coding RNAs, histone modifications, and DNA methylation, play a crucial role in the pathogenesis of diabetic cardiomyopathy and represent potential therapeutic targets.
Why the study?
Because epigenetic modifiers play a crucial role in diabetic cardiomyopathy pathogenesis, exploring their regulation of associated molecular pathways is important.
Epigenetic modifications are key drivers of the molecular pathways underlying diabetic cardiomyopathy, highlighting their potential as novel therapeutic targets.
Supports further exploration of epigenetic targets in diabetic cardiomyopathy; leaves open clinical translation pending interventional studies.
Diabetes mellitus (DM) is an important lifestyle disease. Type 2 diabetes is one of the prime contributors to cardiovascular diseases (CVD) and diabetic cardiomyopathy (DbCM) and leads to increased morbidity and mortality in patients with DM. DbCM is a typical cardiac disease, characterized by cardiac remodeling in the presence of DM and in the absence of other comorbidities such as hypertension, valvular diseases, and coronary artery disease. DbCM is associated with defective cardiac metabolism, altered mitochondrial structure and function, and other physiological and pathophysiological signaling mechanisms such as oxidative stress, inflammation, myocardial apoptosis, and autophagy. Epigenetic modifiers are crucial players in the pathogenesis of DbCM. Thus, it is important to explore the role of epigenetic modifiers or modifications in regulating molecular pathways associated with DbCM. In this review, we have discussed the role of various epigenetic mechanisms such as histone modifications (acetylation and methylation), DNA methylation and non-coding RNAs in modulating molecular pathways involved in the pathophysiology of the DbCM.
No takes yet. Share an insight, caveat, or question.
Mittal et al. (2021) conducted a review in Diabetic Cardiomyopathy. Epigenetic modulators was evaluated. Epigenetic modifications, including non-coding RNAs, histone modifications, and DNA methylation, play a crucial role in the pathogenesis of diabetic cardiomyopathy and represent potential therapeutic targets.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: